Chang et al. also found that in the analysis of NSCLC patients treated with pemetrexed as a third- or fourth-line therapeutic agent, the expression level of TS was not significantly correlated with the clinicopathological factors [28]. Here, TYMS is linked to non-small cell lung carcinoma.